Eagle Pharmaceuticals. has been granted a patent for a method to treat postoperative nausea and vomiting (PONV) using amisulpride. The treatment involves administering amisulpride intravenously at a dose of 9.5 to 10.5 mg to patients who have received prior prophylaxis. GlobalData’s report on Eagle Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Eagle Pharmaceuticals, Nanoparticle drug conjugates was a key innovation area identified from patents. Eagle Pharmaceuticals's grant share as of June 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12005042B2 outlines a method for treating postoperative nausea and vomiting (PONV) in patients through the administration of amisulpride. Specifically, the method involves administering amisulpride at a dosage between 9.5 mg and 10.5 mg via intravenous (IV) infusion, with the infusion duration ranging from approximately 20 seconds to 20 minutes. This treatment is intended for patients who have already received a non-amisulpride prophylactic drug prior to surgery, which is not a dopamine-2 (D2) antagonist. The prophylactic drugs can include various anti-emetics such as 5HT3 antagonists, corticosteroids, anti-histamines, anti-cholinergics, H2-antagonists, and NK1-antagonists.
Additionally, the patent claims that amisulpride can be administered in conjunction with other anti-emetics, either sequentially or simultaneously, with specific examples including dexamethasone, ondansetron, granisetron, palonosetron, aprepitant, netupitant, or rolapitant. The administration of amisulpride is recommended to occur within one hour following the first emetic or nausea episode, with optimal timing suggested to be within 30 minutes or even 15 minutes post-episode. The method also specifies that amisulpride can be administered as a single daily dose, with a preferred dosage of 10 mg, and emphasizes that the drug is to be delivered in a racemic form. This patent provides a structured approach to managing PONV, potentially enhancing patient recovery outcomes following surgical procedures.
To know more about GlobalData’s detailed insights on Eagle Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
